keyword
MENU ▼
Read by QxMD icon Read
search

pulmonary fibrosis randomized controlled trial

keyword
https://www.readbyqxmd.com/read/29898704/acute-effects-of-combined-exercise-and-oscillatory-positive-expiratory-pressure-therapy-on-sputum-properties-and-lung-diffusing-capacity-in-cystic-fibrosis-a-randomized-controlled-crossover-trial
#1
Thomas Radtke, Lukas Böni, Peter Bohnacker, Marion Maggi-Beba, Peter Fischer, Susi Kriemler, Christian Benden, Holger Dressel
BACKGROUND: Regular airway clearance by chest physiotherapy and/or exercise is critical to lung health in cystic fibrosis (CF). Combination of cycling exercise and chest physiotherapy using the Flutter® device on sputum properties has not yet been investigated. METHODS: This prospective, randomized crossover study compared a single bout of continuous cycling exercise at moderate intensity (experiment A, control condition) vs a combination of interval cycling exercise plus Flutter® (experiment B)...
June 14, 2018: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/29890086/azithromycin-for-early-pseudomonas-infection-in-cystic-fibrosis-the-optimize-randomized-trial
#2
Nicole Mayer-Hamblett, George Retsch-Bogart, Margaret Kloster, Frank Accurso, Margaret Rosenfeld, Gary Albers, Philip Black, Perry Brown, AnneMarie Cairns, Stephanie D Davis, Gavin R Graff, Gwendolyn S Kerby, David Orenstein, Rachael Buckingham, Bonnie W Ramsey
RATIONALE: New isolation of Pseudomonas aeruginosa (Pa) is generally treated with inhaled antipseudomonal antibiotics such as tobramycin inhalation solution (TIS). A therapeutic approach complementing traditional antimicrobial therapy by reducing the risk of pulmonary exacerbation (PEx) and inflammation may ultimately prolong time to Pa recurrence. OBJECTIVES: To test the hypothesis that the addition of azithromycin to TIS in children with CF and early Pa decreases the risk of PEx and prolongs time to Pa recurrence...
June 11, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29867501/proton-pump-inhibitors-in-ipf-a-call-for-clinical-trials
#3
REVIEW
Yohannes T Ghebre
The recent FDA approval of two drugs, pirfenidone and nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF) has fueled interest in the development of additional drugs to treat the disease or its major clinical complications including cough and acute exacerbations. Since 2015, there are at least a dozen active interventional studies that are testing the efficacy of novel pharmacotherapies, exercise or stem cells in modifying the disease process in IPF. Additionally, there are combinatorial studies evaluating the effectiveness of pirfenidone or nintedanib in combination with other agents...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29843523/short-and-long-term-effects-of-pulmonary-rehabilitation-for-idiopathic-pulmonary-fibrosis-a-systematic-review-and-meta-analysis
#4
Li Cheng, Botao Tan, Ying Yin, Sanrong Wang, Lang Jia, Gerry Warner, Gongwei Jia, Wei Jiang
OBJECTIVE: To investigate the short- and long-term effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis (IPF). DATA SOURCES: An electronic search of MEDLINE, Embase and Cochrane Central databases along with hand search of relevant papers were performed on 15 March 2018. REVIEW METHODS: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines...
May 1, 2018: Clinical Rehabilitation
https://www.readbyqxmd.com/read/29800034/effect-of-recombinant-human-pentraxin-2-vs-placebo-on-change-in-forced-vital-capacity-in-patients-with-idiopathic-pulmonary-fibrosis-a-randomized-clinical-trial
#5
Ganesh Raghu, Bernt van den Blink, Mark J Hamblin, A Whitney Brown, Jeffrey A Golden, Lawrence A Ho, Marlies S Wijsenbeek, Martina Vasakova, Alberto Pesci, Danielle E Antin-Ozerkis, Keith C Meyer, Michael Kreuter, Hugues Santin-Janin, Geert-Jan Mulder, Brian Bartholmai, Renu Gupta, Luca Richeldi
Importance: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with poor prognosis. Approved therapies do not halt disease progression. Objective: To determine the effect of recombinant human pentraxin 2 vs placebo on change from baseline to week 28 in mean forced vital capacity (FVC) percentage of predicted value. Design, Setting, and Participants: Phase 2, randomized, double-blind, placebo-controlled trial conducted at 18 sites in 7 countries of eligible patients with IPF (N = 117; aged 40-80 years; FVC ≥50% and ≤90% predicted; ratio of forced expiratory volume in the first second/FVC >0...
May 20, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29761573/using-fat-to-fight-disease-a-systematic-review-of-non-homologous-adipose-derived-stromal-stem-cell-therapies
#6
REVIEW
Marjorie E Bateman, Amy L Strong, Jeffrey M Gimble, Bruce A Bunnell
OBJECTIVE: The objective of this review is to describe the safety and efficacy of ASC and SVF in treating common diseases and the next steps in research that must occur prior to clinical use. EVIDENCE REVIEW: Pubmed, Ovid Medline, Embase, Web of Science, and the Cochrane Library were searched for articles about use of SVF or ASC for disease therapy published between 2012 and 2017. One meta-analysis, 2 randomized controlled trials, and 16 case series were included, representing 844 human patients...
May 15, 2018: Stem Cells
https://www.readbyqxmd.com/read/29688760/effects-of-an-antioxidant-enriched-multivitamin-in-cystic-fibrosis-randomized-controlled-multicenter-trial
#7
Scott D Sagel, Umer Khan, Raksha Jain, Gavin Graff, Cori L Daines, Jordan M Dunitz, Drucy Borowitz, David M Orenstein, Ibrahim Abdulhamid, Julie Noe, John P Clancy, Bonnie Slovis, Michael J Rock, Karen S McCoy, Steven Strausbaugh, Floyd R Livingston, Konstantinos A Papas, Michele L Shaffer
RATIONALE: Cystic fibrosis (CF) is characterized by dietary antioxidant deficiencies, which may contribute to an oxidant-antioxidant imbalance and oxidative stress. OBJECTIVES: Evaluate the effects of an oral antioxidant-enriched multivitamin supplement on antioxidant concentrations, markers of inflammation and oxidative stress, and clinical outcomes. METHODS: In this investigator-initiated, multicenter, randomized, double-blind, controlled trial, 73 pancreatic insufficient CF subjects 10 years of age and older with an FEV1 between 40-100% predicted were randomized to 16 weeks of an antioxidant-enriched multivitamin or control multivitamin without antioxidant enrichment...
April 24, 2018: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/29669883/impact-of-long-term-erythromycin-therapy-on-the-oropharyngeal-microbiome-and-resistance-gene-reservoir-in-non-cystic-fibrosis-bronchiectasis
#8
Jocelyn M Choo, Guy C J Abell, Rachel Thomson, Lucy Morgan, Grant Waterer, David L Gordon, Steven L Taylor, Lex E X Leong, Steve L Wesselingh, Lucy D Burr, Geraint B Rogers
Long-term macrolide therapy reduces rates of pulmonary exacerbation in bronchiectasis. However, little is known about the potential for macrolide therapy to alter the composition and function of the oropharyngeal commensal microbiota or to increase the carriage of transmissible antimicrobial resistance. We assessed the effect of long-term erythromycin on oropharyngeal microbiota composition and the carriage of transmissible macrolide resistance genes in 84 adults with bronchiectasis, enrolled in the Bronchiectasis and Low-dose Erythromycin Study (BLESS) 48-week placebo-controlled trial of twice-daily erythromycin ethylsuccinate (400 mg)...
April 25, 2018: MSphere
https://www.readbyqxmd.com/read/29443739/effects-of-exercise-on-secretion-transport-inflammation-and-quality-of-life-in-patients-with-noncystic-fibrosis-bronchiectasis-protocol-for-a-randomized-controlled-trial
#9
RANDOMIZED CONTROLLED TRIAL
Daniele Oliveira Dos Santos, Hugo Celso Dutra de Souza, José Antônio Baddini-Martinez, Ercy Mara Cipulo Ramos, Ada Clarice Gastaldi
BACKGROUND: Bronchiectasis is characterized by pathological and irreversible bronchial dilatation caused by the inefficient mucus and microorganism clearance and progression of inflammatory processes. The most frequent characteristic is the increase in bronchial mucus production resulting in slower transport and damage to the mucociliary transport. AIMS: To evaluate the effects of exercise on mucus transport, inflammation, and resistance of the respiratory and autonomic nervous systems and subsequent effects on quality of life in patients with bronchiectasis who are enrolled in a pulmonary rehabilitation program...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29411860/self-management-for-bronchiectasis
#10
REVIEW
Carol Kelly, Seamus Grundy, Dave Lynes, David Jw Evans, Sharada Gudur, Stephen J Milan, Sally Spencer
BACKGROUND: Bronchiectasis is a long term respiratory condition with an increasing rate of diagnosis. It is associated with persistent symptoms, repeated infective exacerbations, and reduced quality of life, imposing a burden on individuals and healthcare systems. The main aims of therapeutic management are to reduce exacerbations and improve quality of life. Self-management interventions are potentially important for empowering people with bronchiectasis to manage their condition more effectively and to seek care in a timely manner...
February 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29384901/acupuncture-for-idiopathic-pulmonary-fibrosis-protocol-for-a-systematic-review
#11
REVIEW
Yang Xie, Jia-Jia Wang, Gao-Yang Li, Xuan-Lin Li, Jian-Sheng Li
BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) often suffer from progressive worsening of dyspnea and lung function. Although 2 drugs are now available for IPF treatment, many gaps are still to be filled. Evidences suggest that there may be some beneficial effect of acupuncture on pulmonary diseases. This review aims to systematically determine the efficacy and safety of acupuncture for treating IPF. METHODS: The following 8 databases will be searched from their inception to March 20, 2017: PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Chongqing VIP, and Wanfang Data...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29351129/impact-of-pulmonary-rehabilitation-on-exercise-tolerance-and-quality-of-life-in-patients-with-idiopathic-pulmonary-fibrosis-a-systematic-review-and-meta-analysis
#12
Mansueto Gomes-Neto, Cassio Magalhães Silva, Diego Ezequiel, Cristiano Sena Conceição, Micheli Saquetto, Adelmir Souza Machado
BACKGROUND: Patients with pulmonary fibrosis are living longer and present with an increasing number of comorbidities over time. Pulmonary rehabilitation, as a nonpharmacological approach, may be promising in these patients, although there is limited information on the impact of pulmonary rehabilitation on exercise tolerance and quality of life. Thus, conducting a systematic review and meta-analysis, the purpose of this study was to determine the effects of pulmonary rehabilitation on exercise tolerance and quality of life in patients with idiopathic pulmonary fibrosis...
January 18, 2018: Journal of Cardiopulmonary Rehabilitation and Prevention
https://www.readbyqxmd.com/read/29335860/effectiveness-and-safety-of-chinese-medicine-for-idiopathic-pulmonary-fibrosis-a-systematic-review-and-meta-analysis
#13
Qi Wu, Yao Zhou, Fan-Chao Feng, Xian-Mei Zhou
OBJECTIVE: To evaluate the effectiveness and safety of Chinese medicine (CM) for Idiopathic pulmonary fifibrosis (IPF) patients. METHODS: To screened relevant articles, PubMed, Cochrane Library, Excerpta Medica Datase (EMBASE), China National Knowledge Infrastructure (CNKI), Chinese VIP Information (VIP), Wanfang Database and Chinese Biomedical Database (CBM) were searched in English or Chinese until December 2015 for randomized controlled trials, which compared CM treatment (CM group) with Western medicine or placebo (control group) on IPF...
January 15, 2018: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/29325675/mycophenolate-mofetil-as-a-therapeutic-agent-for-interstitial-lung-diseases-in-systemic-sclerosis
#14
REVIEW
Takahiro Ueda, Takuro Sakagami, Toshiaki Kikuchi, Toshinori Takada
Systemic sclerosis (SSc) is an intractable disease that causes fibrosis in all organs. Approximately 40% of patients with SSc have some degree of interstitial lung disease (ILD). One third of patients with SSc and ILD, approximately 15% of all patients, have pulmonary lesions, which slowly progress to respiratory failure resistant to corticosteroid and other treatments. A randomized controlled trial conducted in the United States indicated that one year of treatment with oral cyclophosphamide in patients with SSc-ILD had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and health-related quality of life...
January 2018: Respiratory Investigation
https://www.readbyqxmd.com/read/29298459/embolisation-for-pulmonary-arteriovenous-malformation
#15
REVIEW
Charlie C-T Hsu, Gigi Nc Kwan, Hannah Evans-Barns, Mieke L van Driel
BACKGROUND: Pulmonary arteriovenous malformations are abnormal direct connections between the pulmonary artery and pulmonary vein which result in a right-to-left shunt. They are associated with substantial morbidity and mortality mainly from the effects of paradoxical emboli. Potential complications include stroke, cerebral abscess, pulmonary haemorrhage and hypoxaemia. Embolisation is an endovascular intervention based on the occlusion of the feeding arteries the pulmonary arteriovenous malformations thus eliminating the abnormal right-to-left-shunting...
January 4, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29245325/suspected-accelerated-disease-progression-after-discontinuation-of-nintedanib-in-patients-with-idiopathic-pulmonary-fibrosis-two-case-reports
#16
Satoshi Okamori, Takanori Asakura, Keita Masuzawa, Hiroyuki Yasuda, Hirofumi Kamata, Makoto Ishii, Tomoko Betsuyaku
RATIONAL: The efficacy of nintedanib, a multitarget receptor tyrosine kinase inhibitor, has been demonstrated in recent randomized controlled trials involving patients with idiopathic pulmonary fibrosis (IPF). However, accelerated disease progression after nintedanib discontinuation has never been reported. PATIENT CONCERNS: We report 2 cases involving patients with a history of IPF who presented with respiratory deterioration at 3 weeks after the discontinuation of nintedanib therapy for IPF...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29199116/repaglinide-versus-insulin-for-newly-diagnosed-diabetes-in-patients-with-cystic-fibrosis-a-multicentre-open-label-randomised-trial
#17
Manfred Ballmann, Dominique Hubert, Baroukh M Assael, Doris Staab, Alexandra Hebestreit, Lutz Naehrlich, Tanja Nickolay, Nicole Prinz, Reinhard W Holl
BACKGROUND: As survival among patients with cystic fibrosis has improved in recent decades, complications have become increasingly relevant. The most frequent complication is cystic-fibrosis-related diabetes. The recommended treatment is injected insulin, but some patients are treated with oral antidiabetic drugs to ease the treatment burden. We assessed the efficacy and safety of oral antidiabetic drugs. METHODS: We did a multicentre, open-label, comparative, randomised trial in 49 centres in Austria, France, Germany, and Italy...
February 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29151428/continuous-positive-airway-pressure-in-patients-with-obstructive-sleep-apnea-and-non-alcoholic-steatohepatitis-a-systematic-review-and-meta-analysis
#18
Gonzalo Labarca, Rodrigo Cruz, Jorge Jorquera
STUDY OBJECTIVES: Several studies have reported an association between obstructive sleep apnea (OSA) and several extra-pulmonary issues, such as arterial hypertension and insulin resistance. In recent years, the associations between OSA, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis (NASH) have been published; however, there is a gap between experimental and clinical studies regarding the efficacy of continuous positive airway pressure (CPAP) treatment in patient populations with these conditions...
November 15, 2017: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/29112181/vitamin-d-supplementation-in-respiratory-diseases-evidence-from-randomized-controlled-trials
#19
Carolien Mathyssen, Ghislaine Gayan-Ramirez, Roger Bouillon, Wim Janssens
Pulmonary diseases are one of the most important causes of morbidity and mortality. Although vitamin D is best known for its role in calcium, phosphorus, and bone homeostasis, it has gained attention in the recent years because of a wide range of extraskeletal effects, including its immunomodulatory and antibacterial potential. Vitamin D deficiency is highly prevalent in chronic pulmonary diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, tuberculosis, and asthma, and several clinical studies have been conducted investigating the effect of vitamin D supplementation on disease outcomes...
November 30, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29100885/a-phase-ii-clinical-trial-of-low-dose-inhaled-carbon-monoxide-in-idiopathic-pulmonary-fibrosis
#20
Ivan O Rosas, Hilary J Goldberg, Harold R Collard, Souheil El-Chemaly, Kevin Flaherty, Gary M Hunninghake, Joseph A Lasky, David J Lederer, Roberto Machado, Fernando J Martinez, Rie Maurer, Danielle Teller, Imre Noth, Elizabeth Peters, Ganesh Raghu, Joe G N Garcia, Augustine M K Choi
BACKGROUND: Preclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF). METHODS: We conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice weekly, for 12 weeks...
January 2018: Chest
keyword
keyword
76973
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"